IP Library Granted Patent US 8,809,401
Granted Patent B2
US 8,809,401 · App. 13/579,824 · Granted Aug 19, 2014

Composition with improved skin penetration for transdermal delivery of tolterodine

Inventors: Yong Youn Hwang (Gyeonggi-do, KR); Won-Jae Choi (Seoul-si, KR); Jae-Sun Kim (Gyeonggi-do, KR); Yeo-Jin Park (Seoul-si, KR); Joon-Gyo Oh (Gyeonggi-do, KR); Bong-Yong Lee (Seoul-si, KR); Hae-In Rhee (Gyeonggi-do, KR); Jong-Seob Im (Gyeonggi-do, KR)
Assignee: SK Chemicals Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,401
App. No.
13/579,824
Granted
Aug 19, 2014
Kind
B2
Abstract

Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Claims (4)

1. A composition for transdermal administration comprising tolterodine, characterized in that the composition comprises lidocaine or its pharmaceutically acceptable salt to enhance the skin penetration of tolterodine, wherein the lidocaine or its pharmaceutically acceptable salt is used in an amount of 1 to 300 parts by weight, based on 100 parts by weight of the tolterodine.

2. A composition for transdermal administration comprising tolterodine, characterized in that the composition comprises lidocaine or its pharmaceutically acceptable salt to enhance the skin penetration of tolterodine, wherein the composition comprises 100 parts by weight of the tolterodine, 500 to 5,000 parts by weight of an adhesive acrylate copolymer, and 1 to 300 parts by weight of the lidocaine or its pharmaceutically acceptable salt.

3. The composition for transdermal administration according to claim 1 , wherein the tolterodine is in the form of free base.

4. The composition for transdermal administration according to claim 2 , wherein the tolterodine is in the form of free base.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2012
From: HWANG, YONG YOUN; CHOI, WON JAE; KIM, JAE SUN; PARK, YEO JIN; OH, JOON GYO; LEE, BONG YONG; RHEE, HAE IN; IM, JONG SEOB
To: SK CHEMICALS CO., LTD.
Reel/Frame 029224/0645 →
Priority Claims (1)
KR 10-2010-0014554 · Feb 18, 2010 · national
Continuity (1)
Related Publication 20130046026A1 · Feb 21, 2013